Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $26.35 USD
Change Today 0.00 / 0.00%
Volume 0.0
GHDX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

genomic health inc (GHDX) Snapshot

Open
$26.88
Previous Close
$27.52
Day High
$27.17
Day Low
$25.96
52 Week High
10/31/14 - $37.74
52 Week Low
08/24/15 - $23.00
Market Cap
855.9M
Average Volume 10 Days
272.3K
EPS TTM
$-0.99
Shares Outstanding
32.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GENOMIC HEALTH INC (GHDX)

genomic health inc (GHDX) Related Businessweek News

View More BusinessWeek News

genomic health inc (GHDX) Details

Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

752 Employees
Last Reported Date: 03/12/15
Founded in 2000

genomic health inc (GHDX) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $660.0K
Co-Founder and Chief Scientific Officer
Total Annual Compensation: $475.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2014.

genomic health inc (GHDX) Key Developments

Genomic Health Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 01:15 PM

Genomic Health Inc. Presents at UBS Genomics 2.0 Summit, Aug-13-2015 01:15 PM. Venue: The St. Regis Deer Valley, Park City, Utah, United States. Speakers: Kimberly J. Popovits, Chairman, Chief Executive Officer, President and Member of Non-Management Stock Option Committee.

Genomic Health, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Revises Earnings Guidance for the Full Year Ending December 31, 2015

Genomic Health Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported product revenues of $70.619 million against $70.477 million a year ago. Loss from operations was $10.832 million against $4.611 million a year ago. Loss before income taxes was $10.452 million against $4.530 million a year ago. Net loss was $9.237 million or $0.29 per basic and diluted share against $4.618 million or $0.15 per basic and diluted share a year ago. The increased net loss is primarily a result of the company’s investment in key areas for growth, all of which contributed to record levels of tests delivered in the second quarter. For the six months, the company reported product revenues of $138.771 million against $137.479 million a year ago. Loss from operations was $25.501 million against $11.805 million a year ago. Loss before income taxes was $25.441 million against $11.900 million a year ago. Net loss was $18.730 million or $0.58 per basic and diluted share against $12.063 million or $0.39 per basic and diluted share a year ago. On a constant currency basis, revenue increased 2% compared with the same period in the prior year. The company provided earnings guidance for the full year ending December 31, 2015. For the year, the company is updating its financial guidance for the full year ending December 31, 2015, to reflect the estimated change in foreign currency rates: Revenue of $289 million to $302 million (formerly expected in the range of $292 to $305 million). Net loss expected in the range of between $19 and $26 million (formerly expected in the range of $17 and $24 million), or basic net loss per share of between $0.59 and $0.81, and Oncotype DX tests delivered of 102,000 to 109,000 (unchanged). While the company is adjusting its financial guidance to reflect an estimated $3 million impact on revenue from the effect of foreign exchange rates, its expectations regarding the level of Oncotype DX tests remain unchanged, reflecting the strong growth across markets that the company has delivered in the first half of the year.

Urology Practice Publishes Genomic Health Inc.'s Results from the Second Clinical Utility Study of the Oncotype DX® Prostate Cancer Test

Genomic Health Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test's Genomic Prostate Score (GPS) in treatment planning resulted in greater recommendations and acceptance of active surveillance as initial management of prostate cancer in low and low-intermediate risk patients. The multi-center study included 211 patients from 10 sites across the United States. The review of patient charts showed a relative increase of 56% in use of active surveillance in patients who received their Oncotype DX GPS compared to patients from the same practices with similar risk factors who were not tested. Additionally, the results showed an increase in physician recommendation of active surveillance that was consistent with a previous prospective clinical study published earlier this year. Together, the two published clinical utility studies demonstrate that use of Oncotype DX changes both treatment recommendations and actual treatment received, resulting in greater recommendation and adoption of active surveillance. The Oncotype DX® portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumor in order to optimize cancer treatment decisions. The Oncotype DX prostate cancer test identifies which clinically low-risk patients are eligible for active surveillance, as well as those who may benefit from immediate treatment by predicting disease aggressiveness.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GHDX:US $26.35 USD 0.00

GHDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alliance HealthCare Services Inc $13.91 USD 0.00
Enzo Biochem Inc $2.89 USD 0.00
Foundation Medicine Inc $22.93 USD 0.00
NanoString Technologies Inc $14.65 USD 0.00
NeoGenomics Inc $5.94 USD 0.00
View Industry Companies
 

Industry Analysis

GHDX

Industry Average

Valuation GHDX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.2x
Price/Book 5.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GENOMIC HEALTH INC, please visit www.genomichealth.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.